The proceeds will be used for the advancement of its first two product pipelines.
Chimigen Bio recently announced the completion of its first financing round valued at more than 100 million CNY.
The round was led by Lapam Capital, with participation from Puhua Capital, Nanjing Jianyou and other institutes. Hejun Capital acted as the exclusive financial advisor.
The proceeds will be used to accelerate the first two products into clinical trials, international team expansion and talent acquisition.
Founded in 2021, Chimigen Bio is a biotech company specializing in the development of anti-viral and anti-tumor immunotherapies. Its proprietary innovative vaccine platform, SynNeogen, has the dual characteristics of antigen and antibody, which can simulate the whole process of the uptake, processing and presentation of the natural antigen of the human body, and further induce a broad immune response with antigen-specific multiple epitopes.